Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer Sparano, J. A., Zhao, F., Martino, S., Ligibel, J., Saphner, T., Wolff, A. C., Sledge, G. W., Perez, E. A., Wood, W. C., Davidson, N. E. AMER ASSOC CANCER RESEARCH. 2015
View details for DOI 10.1158/1538-7445.SABCS14-S3-03
View details for Web of Science ID 000356730200020